Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chen, Szu Chia ^a,b,c   Hung, Chi Chih ^a,c   Kuo, Mei Chuan ^a,c   Lee, Jia Jung ^a,c   Chiu, Yi Wen ^a,c   Chang, Jer Ming ^a,b,c   Hwang, Shang Jyh ^a,c   Chen, Hung Chun ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY TRANSPLANTATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; RAPID RENAL PROGRESSION;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; ODDS RATIO; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 84873520316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055643     Document Type: Article

References (31)

1. Vaziri ND, Norris K, (2011) Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31: 189-196.
2. Vaziri ND, (2006) Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-272.
3. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 106: 3143-3421.
4. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829-1839.
5. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, et al. (2010) Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 21: 2131-2142.
6. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, et al. (1999) Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int (Suppl 71): pp. S47-50.
7. Vazquez-Perez S, Aragoncillo P, de Las Heras N, Navarro-Cid J, Cediel E, et al. (2001) Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant 16 (Suppl 1):: 40-44.
8. Chen HC, Guh JY, Shin SJ, Lai YH, (2002) Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-ldl and high glucose. Atherosclerosis 160: 141-146.
9. Chen HC, Guh JY, Shin SJ, Tomino Y, Lai YH, (2002) Effects of pravastatin on superoxide and fibronectin production of mesangial cells induced by low-density lipoprotein. Kidney Blood Press Res 25: 2-6.
10. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, et al. (2003) Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091.
11. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH, (2001) Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60: 277-283.
12. Chawla V, Greene T, Beck GJ, Kusek JW, Collins AJ, et al. (2010) Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 5: 1582-1587.
13. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, et al. (2011) The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomised placebo-controlled trial. Lancet 377: 2181-2192.
14. Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, et al. (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130: 461-470.
16. Vaziri ND, Moradi H, (2006) Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10: 1-7.
17. Rovin BH, Tan LC, (1993) Ldl stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43: 218-225.
18. Abrass CK, (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24: 46-53.
19. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ, (2000) Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58: 293-301.
20. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, et al. (2004) Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459.
21. Iseki K, Yamazato M, Tozawa M, Takishita S, (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61: 1887-1893.
22. Kopple JD, (2005) The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr 81: 1257-1266.
23. Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA, (2007) Reverse epidemiology: A confusing, confounding, and inaccurate term. Semin Dial 20: 586-592.
24. Chen SC, Lin TH, Hsu PC, Chang JM, Lee CS, et al. (2011) Impaired left ventricular systolic function and increased brachial-ankle pulse-wave velocity are independently associated with rapid renal function progression. Hypertens Res 34: 1052-1058.
25. Chen SC, Su HM, Hung CC, Chang JM, Liu WC, et al. (2011) Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol 6: 2750-2758.
26. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, et al. (2001) C reactive protein in patients with chronic renal diseases. Ren Fail 23: 551-562.
27. Fried LF, Orchard TJ, Kasiske BL, (2001) Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269.
28. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, et al. (2001) Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21: 449-454.
29. Sandhu S, Wiebe N, Fried LF, Tonelli M, (2006) Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17: 2006-2016.
30. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, et al. (2006) The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21: 3106-3114.
31. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, et al. (2008) Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). Am J Kidney Dis 52: 412-424.